Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain.

ABSTRACT: The CB₂ R agonist AM1710, examined in animal models of peripheral neuropathy, is effective in controlling aberrant light touch sensitivity, referred to as mechanical allodynia. However, nonspecific binding of AM1710 to CB₁ R, either peripherally or centrally, could be partially responsible for the analgesic effects of AM1710. Thus, we sought to determine in mice whether spinal (intrathecal; i.t.) or peripheral AM1710 administration could lead to anti-allodynia by reducing the protein expression of spinal and dorsal root ganglia (DRG) proinflammatory cytokines and elevating the anti-inflammatory cytokine interleukin-10 (IL-10) in the absence of CB₁ R. Macrophage cell cultures were examined to characterize AM1710-mediated suppression of the proinflammatory cy

SUBMITTER: Wilkerson JL 

PROVIDER: S-EPMC7749576 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature